Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck pharmaceutical Sales — Eastern Europe / Middle East / Africa ($M) ($M)
Form 8-K Supplemental Table 3c / 3b (Pharmaceutical Geographic Sales)
Latest, FY2025
1,598
Period ended Dec 31, 2025
Change on a year earlier
+6.9%
1,495 in FY2024
History
7 years
Since FY2019
Sources
7
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Pharmaceutical Sales — Eastern Europe / Middle East / Africa ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,598 | +6.9% | Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗ |
| FY2024 | Dec 31, 2024 | 1,495 | +10.7% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 1,351 | -8.0% | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 1,469 | +11.7% | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2021 | Dec 31, 2021 | 1,315 | +9.7% | Form 8-K (tm235007d1_ex99-1.htm, filed 2023-02-02) ↗ |
| FY2020 | Dec 31, 2020 | 1,199 | -24.0% | Form 8-K (tm2131077d1_ex99-1.htm, filed 2021-10-28) ↗ |
| FY2019 | Dec 31, 2019 | 1,577 | – | Form 8-K (tm2032785d1_ex99-1.htm, filed 2020-10-27) ↗ |
Breakdown
What makes up pharmaceutical sales — eastern europe / middle east / africa ($m)
Cite this data
StockData. (2026). Merck Pharmaceutical Sales — Eastern Europe / Middle East / Africa ($M) ($M), annual FY2019–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/pharma_geo_eemea
See every metric in the Merck KPI table. Data updated Oct 26, 2026.